Personalis, Inc. (NASDAQ:PSNL) Stock Has Average Target Price of $14.54 According to Analysts

Personalis, Inc. (NASDAQ:PSNL) has been given a consensus recommendation of “Hold” by the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $14.54.

Several equities analysts recently issued reports on the stock. Lake Street Capital cut shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a research note on Monday, July 20th. BTIG Research lowered shares of Personalis from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 6th. Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Zacks Research raised shares of Personalis from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Finally, Morgan Stanley upped their price objective on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th.

Insiders Place Their Bets

In related news, CFO Aaron Tachibana sold 2,931 shares of Personalis stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $47,540.82. Following the completion of the transaction, the chief financial officer owned 195,902 shares in the company, valued at $3,177,530.44. The trade was a 1.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Christopher Hall sold 7,459 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total value of $120,984.98. Following the completion of the transaction, the chief executive officer directly owned 228,527 shares of the company’s stock, valued at $3,706,707.94. The trade was a 3.16% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 16,456 shares of company stock valued at $266,916 over the last quarter. Insiders own 4.20% of the company’s stock.

Institutional Trading of Personalis

Several institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. Quantbot Technologies LP acquired a new position in Personalis during the second quarter worth $69,000. ADAR1 Capital Management LLC acquired a new position in Personalis during the first quarter worth $159,000. Fortitude Family Office LLC purchased a new position in Personalis in the 3rd quarter valued at about $164,000. Finally, Penobscot Investment Management Company Inc. acquired a new stake in Personalis in the 3rd quarter worth about $182,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Personalis Trading Up 0.1%

Shares of PSNL stock opened at $16.00 on Thursday. The stock has a 50 day moving average of $16.36 and a 200 day moving average of $11.24. The stock has a market cap of $1.68 billion, a P/E ratio of -14.68 and a beta of 2.32. Personalis has a twelve month low of $4.95 and a twelve month high of $18.89.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.

About Personalis

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.